Number of suitable people: CDEC talked about the uncertainty in the quantity of sufferers with moderately critical to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some clients that are labeled as obtaining gentle or moderate disease may have a severe bleeding phenotype